Jason McNair
Family Medicine · Kingwood, WVNPI 1770926537
Payments from drug & device makers
Across 76 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$189
- Lilly USA, LLC$161
- Xeris Pharmaceuticals, Inc.$142
- Pfizer$106
- Dendreon Pharmaceuticals LLC$87
- Novartis$65
- plus $592 from 20 others
What the payments were for
- Food & beverage$1,342100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $189 |
| Lilly USA, LLC | 9 | $161 |
| Xeris Pharmaceuticals, Inc. | 7 | $142 |
| Pfizer | 7 | $106 |
| Dendreon Pharmaceuticals LLC | 3 | $87 |
| Novartis | 4 | $65 |
| AbbVie(2 entities) | 3 | $61 |
| Intuitive Surgical | 1 | $49 |
| Abbott | 3 | $49 |
| Amarin Pharma, Inc. | 3 | $48 |
| Dexcom, Inc. | 3 | $46 |
| Exact Sciences | 3 | $44 |
| Novo Nordisk | 2 | $36 |
| Lundbeck LLC | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Bayer | 1 | $25 |
| Boehringer Ingelheim | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Organon | 1 | $20 |
| Mylan Specialty L.p. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Amgen | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$1,342 in reported general payments places this provider in the 70th percentile of 843 family medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $142,491 |
| MounjaroTirzepatide | 102 | $135,713 |
| EliquisApixaban | 100 | $112,764 |
| JardianceEmpagliflozin | 50 | $67,200 |
| JanuviaSitagliptin Phosphate | 42 | $47,454 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $38,532 |
| TrulicityDulaglutide | 23 | $30,090 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $28,477 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $26,225 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 19 | $25,475 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $24,699 |
| TradjentaLinagliptin | 19 | $24,155 |
| CreonLipase/Protease/Amylase | 13 | $19,374 |
| XareltoRivaroxaban | 13 | $18,959 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $16,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6 | $36 | $167,966137 claims |
| Lilly USA, LLCMounjaro, Trulicity | $161 | $165,803125 claims |
| PfizerEliquis | $106 | $112,764100 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat | $22 | $103,03893 claims |
| GSKTrelegy Ellipta | $16 | $26,22521 claims |
| AbbVieCreon | $61 | $19,37413 claims |
| AstraZenecaBreztri Aerosphere | $189 | $14,91725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Kingwood
- Wilbur SineMorgantown$179K
- Dorian WilliamsMorgantown$169K
- Julie DetempleSouth Charleston$129K
- Clemente DiazRichwood$127K
- John CornellHuntington$94K
- Mark CucuzzellaHarpers Ferry$59K
- Courtney PilkertonMorgantown$45K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
- Ryan RunyonPrinceton$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.